Obstructive sleep apnea-hypopnea syndrome (OSAHS) is characterized by intermittent partial or complete occlusion of the upper airway, affecting 5 to 10 % of middle-aged adults and up to 20 % of adults over 65 years of age [1]. Treatments for patients with OSAHS include positive airway pressure (PAP) therapy, oral appliances, various surgeries that modify the upper airway, and/or weight loss. However, it is well documented that there is lack of acceptance or suboptimal adherence to these available medical therapies [2, 3]. Therefore, given the high prevalence of OSAHS, new effective treatment options would be welcomed.

Alternative management approaches for OSAHS, less intrusive and simpler to use, have emerged. One of these alternatives is expiratory positive airway pressure (EPAP) nasal device, a small, lightweight, and quiet device that does not require an external power source. There are several mechanisms by which nasal EPAP devices positively impact OSAHS. These disposable adhesive ...